Business Description
Tandem Diabetes Care Inc
NAICS : 339112
SIC : 3841
ISIN : US8753722037
Description
Tandem Diabetes Care Inc designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. Nearly three quarters of total revenue is derived from the U.S., with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.13 | |||||
| Equity-to-Asset | 0.33 | |||||
| Debt-to-Equity | 1.33 | |||||
| Debt-to-EBITDA | -2.12 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 1.5 | |||||
| Beneish M-Score | -2.83 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.1 | |||||
| 3-Year EBITDA Growth Rate | -138.3 | |||||
| 3-Year EPS without NRI Growth Rate | -103.1 | |||||
| 3-Year FCF Growth Rate | -117.4 | |||||
| 3-Year Book Growth Rate | -6.6 | |||||
| Future 3-5Y Total Revenue Growth Rate | 11.54 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.5 | |||||
| 9-Day RSI | 62.3 | |||||
| 14-Day RSI | 59.97 | |||||
| 6-1 Month Momentum % | 87.37 | |||||
| 12-1 Month Momentum % | -10.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.83 | |||||
| Quick Ratio | 3.02 | |||||
| Cash Ratio | 2.4 | |||||
| Days Inventory | 132.87 | |||||
| Days Sales Outstanding | 49.86 | |||||
| Days Payable | 50.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.7 | |||||
| Shareholder Yield % | 0.09 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 49.18 | |||||
| Operating Margin % | -31.19 | |||||
| Net Margin % | -29.77 | |||||
| FCF Margin % | -11.16 | |||||
| ROE % | -64.13 | |||||
| ROA % | -22.97 | |||||
| ROIC % | -61.62 | |||||
| ROC (Joel Greenblatt) % | -81.05 | |||||
| ROCE % | -26.85 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.11 | |||||
| PB Ratio | 7.37 | |||||
| Price-to-Tangible-Book | 7.43 | |||||
| EV-to-EBIT | -10.57 | |||||
| EV-to-Forward-EBIT | -22.91 | |||||
| EV-to-EBITDA | -11.42 | |||||
| EV-to-Forward-EBITDA | -89.87 | |||||
| EV-to-Revenue | 3 | |||||
| EV-to-Forward-Revenue | 2.62 | |||||
| EV-to-FCF | -26.9 | |||||
| Price-to-Projected-FCF | 8.99 | |||||
| Price-to-Median-PS-Value | 0.59 | |||||
| Price-to-Net-Current-Asset-Value | 21.23 | |||||
| Earnings Yield (Greenblatt) % | -9.46 | |||||
| FCF Yield % | -3.67 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers